Gary Espardinez

☕ #Boston, grab you favorite Dunkin’ coffee and join us at the Precision in Clinical Trials Summit May 6 & 7! Stop by Booth #11 to meet the #IDDI experts Tara Kervin & Kalyn D. to discuss how IDDI’s solutions can assist your most pressing clinical trial challenges. 📈 Schedule a meeting today: https://lnkd.in/efjcJffp #PCTSummit #biometricscro #clinicaltrials #biostatistics #datamanagement #lifesciences #trialdesign

10

Will you be at #AMCP2024 this year? This Wednesday, April 17th at 10:45 CT Alnylam’s Sami Nasrawi, PharmD is leading a spotlight presentation: “ATTR Amyloidosis - Disease State Overview.” Join us in Theater 2 to learn more about ATTR #Amyloidosis epidemiology, clinical presentation and diagnosis of both cardiomyopathy and polyneuropathy manifestations. Learn more about AMCP: https://bit.ly/49BEjx1

121

🚀 In 2023, the ICM market soared to $149.8bn across 169 deals! As deal values climb, accurate and timely checkpoint intelligence is critical. Our 2023 Landscape Review offers precise data and exclusive insights to support your development initiatives and boost your pipeline. Summarizing highlights from the drug, trial, and commercial landscapes across 2023, this review equips you with the confidence to navigate the checkpoint space effectively. Access your copy here: https://ter.li/6j8b9p 📥 #Checkpoint #ICMs #Pharma #DrugDevelopment

3

A new BMT CTN study shows that giving gilteritinib after BMT helps people who have FLT3 AML and have MRD. Read more about this study: https://lnkd.in/gT67CWrm

8

1 Comment

🧬 Join the American Pharmacogenomics Association for a FREE online event to discuss hot topics in PGx. ☕️ Here's what you can expect: ✅ Discuss the latest PGx developments ✅ Explore the impact of new legislation ✅ Ask your burning questions Date: Thursday, May 16th Time: 7:30 AM - 8:30 AM PST 🔷 Reserve Your Spot and Register here! https://lnkd.in/g9AVfw_w #pharmacogenomics #genetics #personalizedmedicine #coffee #webinar

10

Tomorrow kicks off the American Society of Clinical Oncology (ASCO) Annual Meeting, where professionals working in #Oncology spend time connecting and collaborating. Find Corcept at Booth #14157 to learn more about the potential role of our proprietary selective #CortisolModulator in platinum-resistant ovarian cancer. #ASCO24 #OvarianCancer #ClinicalResearch #Phase3

105

Can BTK inhibitors tackle cancer and autoimmunity? 🤔 💊 BTK inhibitors are a class of drugs that were initially developed to control the spread of cancer. Now, they are in the running to treat a host of autoimmune diseases.  Currently, Sanofi and Novartis’ drugs seem to be making progress in the clinic. 🏥 But that’s not to say that everything is going well in the field. These drugs have led to serious side effects in patients. 🤒 Read our latest article to find out more about these cancer drugs that are emerging as autoimmune therapies! 👇 https://lnkd.in/dqbBJ8nv #BTKinhibitors #cancertreatment #autoimmunetherapies #medicalresearch #drugdevelopment #healthcareadvancements InnoCare (HKEX: 09969; SSE: 688428) | Biogen | Merck | Gossamer Bio | Oncternal Therapeutics | Johnson & Johnson | AbbVie | Eli Lilly and Company | Loxo@Lilly | AstraZeneca | BeiGene

1

ClinGen Resource's patient registry, GenomeConnect, is at Virginia State Genetics Education Conference #VAAGC. Stop by our booth today to learn more about engaging patients in data sharing. #GCChat #Genetics #DataSharing.

9

Nxera Pharma, formerly Sosei Heptares, is set to receive $4.6 million in milestone payments from Centessa Pharmaceuticals. Centessa licensed Nxera Pharma technology to help design its novel orexin receptor 2 (OX2R) agonist, ORX750. https://lnkd.in/eKXySM7D Nxera, which has R & D facilities in Cambridge, says the milestone was achieved with clearance of the ORX750 Investigational New Drug application and progression of ORX750 into a Phase 1 clinical trial. The drug is designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1, with potential applicability to narcolepsy type 2, idiopathic hypersomnia and other sleep-wake disorders with normal orexin levels. In-demand Nxera also reveals that it has expanded a strategic R & D partnership with PrecisionLife in a new therapeutic area. The collaboration will leverage novel insights into causal biology within auto-immune disorders to identify fresh targets for drug discovery. PrecisionLife is a Causal AI precision medicine specialist. This is the latest in a series of collaborative agreements between Nxera and PrecisionLife, which began in 2022. The partnership aims to establish new drug targets and subsequently potential precision targeted therapies for auto-immune disorders, each linked to subgroups of patients by PrecisionLife’s mechanism-based patient stratification biomarkers. Matt Barnes, EVP, President of Nxera Pharma UK and Head of R & D, said: “PrecisionLife’s platform for enabling unique insight into disease biology supports our approach to identify the ‘right’ drug target and patient subgroups to leverage our world-leading discovery and early development capabilities and increase our probability of success to provide more effective treatments for patients.”

53

Shuttle Pharmaceuticals CEO, Dr. Anatoly Dritschilo, presented at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024. The presentation included an update on the Company’s progress toward clinical and scientific milestones of its Phase 2 Clinical Trial of Ropidoxuridine for treatment of patients with glioblastoma, a deadly malignancy of the brain with no known cure as well as an update on the Company’s plans of its subsidiary, Shuttle Diagnostics, Inc., to develop predictive biomarkers for prostate cancer outcomes following radiation therapy, and novel PSMA ligand for theranostic applications. View presentation: https://lnkd.in/g8etEmRA #SHPH #shuttlepharma #oncology #cancertreatment #radiationtherapy #ropidoxuridine #glioblastoma #prostatecancer 

9

Here are my top 3 studies from American Society of Clinical Oncology (ASCO) 2024 - Laura Bobolts, PharmD, BCOP OncoHealth Nova Southeastern University- College of Pharmacy #ASCO24 #BreastCancer #Cancer #Melanoma #NADINA #OncoDaily #Oncology #StanleyCupFinals

24

Ready for more #ASCO2024 data, hot off the press like hot cakes 🥞(can you tell I’m hungry?) Laura Bobolts, PharmD, BCOP here reporting from the biggest cancer conference in the world! PALMARES-2, an Italian study evaluating the real world efficacy of CDK4/6 inhibitors + endocrine tx in HR+/HER2- metastatic breast cancer (MBC) 👉 Abemaciclib (Verzenio) or Ribociclib (Kisqali) use improved progression-free survival vs Palbociclib (Ibrance) but no significant difference btw Abema compared to Ribo. Many payers prefer Abemaciclib or Ribociclib over Palbociclib today… but they need to be ready for Inavolisib to shake things up! Inavolisib is likely to get FDA approval before Nov 27th in combo w/ ✨Palbociclib✨& Fulvestrant in PIK3CA-mutated, HR+/HER2- MBC w/ recurrence after adjuvant endocrine tx 👉57%⬇️🎉 in the risk of progression or death. Since Inavolisib was only studied w/ Palbo & not Ribo or Abema, payers may need to revisit their strategies in this PIK3CAm population. #ASCO #breastcancer #CDK46inhibitors #Ibrance #Kisqali #Verznio

33

1 Comment

The interim safety and PK/PD profile from the Q901 Phase I study to be presented at ASCO 2024. Commbined with new MOA data presented at AACR 2024, Q901 promises a new treatment option for cancer patients.

17

1 Comment

Dive into our newest Peer Exchange series, where expert panel including Craig Beavers, PharmD, FACC, FAHA,FCCP,BCCP,CACP; Dave Dixon, PharmD, FACC, FAHA, FCCP, FNLA, BCACP, CLS; Joseph Saseen, PharmD, MNLA, FCCP, FAHA, BCPS, BCACP, CLS; Kate Phillips Cabral, PharmD, BCCP, FACC, FCCP; and Kelsey Norman, PharmD, BCCP, BCACP, BCPS, discussed the challenges of achieving LDL cholesterol targets. Enhance your understanding of statin therapy optimization and uncover the barriers to advancing heart health treatment. Start watching the ongoing episodes today: https://bit.ly/49Te1GD.

45

1 Comment

With the challenges facing clinical toxicology laboratories, including POLs, the industry must look beyond the next client acquisition and develop a vision for the future. With an ever-changing market landscape labs must innovate to maintain relevance. No longer is it enough to generate results without context. Providers must quickly grasp essential information and make decisions. SafeDrugs reporting, integrates with existing LIS services to provide additional context related to drug safety. #LCMS #Toxicology #DrugSafety #SafeDrugs #Contraindications #DrugDrugInteractions

1

Danielle L. Hagen, Clinical Supply Manager at Nykode Therapeutics, is stealing the spotlight with her presentation on "Designing a Robust Supply Chain Strategy for Individualized Vaccines" at the 3rd BioPharma Supply Chain & Logistics Nexus Conference! 🎤 Don't miss this opportunity to gain valuable knowledge and network with industry leaders. See you there! 💼✨ #BioPharma #SupplyChain #Logistics #NexusConference #SupplyManagement #LivePresentation 🌐📢

29